• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中期因子是一种潜在的尿液生物标志物,用于非侵入性检测伴有镜下血尿的膀胱癌。

Midkine Is a Potential Urinary Biomarker for Non-Invasive Detection of Bladder Cancer with Microscopic Hematuria.

作者信息

Lin Hao, Zhou Qingwen, Wu Weichu, Ma Yulin

机构信息

Department of Urology, The Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong 515041, People's Republic of China.

Department of Urology, Hongsen Hospital of Harbin Medical University, Sanya, Hainan 572000, People's Republic of China.

出版信息

Onco Targets Ther. 2019 Dec 31;12:11765-11775. doi: 10.2147/OTT.S235134. eCollection 2019.

DOI:10.2147/OTT.S235134
PMID:32099383
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6997436/
Abstract

BACKGROUND

To determine the role of Midkine (MDK) in non-invasive detection of bladder cancer (Bca) and the relationship with Ki67.

METHODS

Sixty-five Bca patients and 55 non-Bca patients or healthy volunteers were enrolled and voided urine samples were prospectively obtained on the first day of enrollment. Tissue samples were collected by surgery. MDK and Ki67 expressions were analyzed by immunohistochemistry and Western Blot (WB). Specificity and sensitivity of MDK mRNA testing in the detection of Bca were determined by Receiver Operating Characteristic curve (ROC). The relationship between MDK and Ki67 was also assessed.

RESULTS

MDK was overexpressed in Bca tissues than that in the non-cancer tissues. The specificity and sensitivity for MDK mRNA testing in urine in the identification of Bca was 80% and 72.3%. MDK detected 85.7% of high-grade tumors, 87.5% of muscle-invasive tumors and 79.4% of tumors larger than 3 cm in patients without gross hematuria. Microscopic hematuria may even increase the detection rate of Bca by MDK testing. Furthermore, the correlation of MDK and Ki67 was found positive.

CONCLUSION

MDK was overexpressed in Bca tissues and positively correlated with Ki67. MDK might be a potential biomarker for the detection of Bca, especially for those without gross hematuria but with microscopic hematuria.

摘要

背景

确定中期因子(MDK)在膀胱癌(Bca)非侵入性检测中的作用及其与Ki67的关系。

方法

招募65例Bca患者和55例非Bca患者或健康志愿者,在入组第一天前瞻性采集晨尿样本。手术采集组织样本。采用免疫组织化学和蛋白质免疫印迹法(WB)分析MDK和Ki67的表达。通过受试者工作特征曲线(ROC)确定MDK mRNA检测在Bca检测中的特异性和敏感性。同时评估MDK与Ki67之间的关系。

结果

与非癌组织相比,MDK在Bca组织中过表达。尿液中MDK mRNA检测识别Bca的特异性和敏感性分别为80%和72.3%。在无肉眼血尿的患者中,MDK检测出85.7%的高级别肿瘤、87.5%的肌层浸润性肿瘤和79.4%直径大于3 cm的肿瘤。镜下血尿甚至可能提高MDK检测对Bca的检出率。此外,发现MDK与Ki67呈正相关。

结论

MDK在Bca组织中过表达且与Ki67呈正相关。MDK可能是Bca检测的潜在生物标志物,尤其对于那些无肉眼血尿但有镜下血尿的患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3864/6997436/7386845c70e7/OTT-12-11765-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3864/6997436/c9f66b44d461/OTT-12-11765-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3864/6997436/4aee10ae0594/OTT-12-11765-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3864/6997436/6b45cb833c3a/OTT-12-11765-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3864/6997436/facac10f3e6b/OTT-12-11765-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3864/6997436/720841461fd2/OTT-12-11765-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3864/6997436/7386845c70e7/OTT-12-11765-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3864/6997436/c9f66b44d461/OTT-12-11765-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3864/6997436/4aee10ae0594/OTT-12-11765-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3864/6997436/6b45cb833c3a/OTT-12-11765-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3864/6997436/facac10f3e6b/OTT-12-11765-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3864/6997436/720841461fd2/OTT-12-11765-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3864/6997436/7386845c70e7/OTT-12-11765-g0006.jpg

相似文献

1
Midkine Is a Potential Urinary Biomarker for Non-Invasive Detection of Bladder Cancer with Microscopic Hematuria.中期因子是一种潜在的尿液生物标志物,用于非侵入性检测伴有镜下血尿的膀胱癌。
Onco Targets Ther. 2019 Dec 31;12:11765-11775. doi: 10.2147/OTT.S235134. eCollection 2019.
2
Over-expression of KRT17 and MDK genes at mRNA levels in urine-exfoliated cells is associated with early non-invasive diagnosis of non-muscle-invasive bladder cancer.尿液脱落细胞中 KRT17 和 MDK 基因 mRNA 水平的过表达与非肌层浸润性膀胱癌的早期无创诊断相关。
Clin Biochem. 2024 Oct;131-132:110808. doi: 10.1016/j.clinbiochem.2024.110808. Epub 2024 Jul 26.
3
Validation of the diagnostic utility of urinary midkine for the detection of bladder cancer.尿中肾损伤分子-1对膀胱癌检测诊断效用的验证
Oncol Lett. 2016 Nov;12(5):3143-3152. doi: 10.3892/ol.2016.5040. Epub 2016 Aug 23.
4
HOXA9, PCDH17, POU4F2, and ONECUT2 as a Urinary Biomarker Combination for the Detection of Bladder Cancer in Chinese Patients with Hematuria.HOXA9、PCDH17、POU4F2 和 ONECUT2 作为血尿中国患者膀胱癌检测的尿液生物标志物组合。
Eur Urol Focus. 2020 Mar 15;6(2):284-291. doi: 10.1016/j.euf.2018.09.016. Epub 2018 Oct 9.
5
Detection of Urothelial Bladder Cancer Based on Urine and Tissue Telomerase Activity Measured by Novel RT-TRAP-2PCR Method.基于新型逆转录-端粒重复扩增-2聚合酶链反应法检测尿液和组织端粒酶活性诊断尿路上皮膀胱癌
J Clin Med. 2021 Mar 4;10(5):1055. doi: 10.3390/jcm10051055.
6
Midkine level may be used as a noninvasive biomarker in Crohn’s disease.中脑星型胶质细胞源性神经营养因子水平可作为克罗恩病的无创性生物标志物。
Turk J Med Sci. 2020 Apr 9;50(2):324-329. doi: 10.3906/sag-1904-167.
7
CCL18 in a multiplex urine-based assay for the detection of bladder cancer.CCL18 在基于多重尿液检测膀胱癌的应用。
PLoS One. 2012;7(5):e37797. doi: 10.1371/journal.pone.0037797. Epub 2012 May 21.
8
The value of serum midkine level in diagnosis of hepatocellular carcinoma.血清中期因子水平在肝细胞癌诊断中的价值。
Int J Hepatol. 2015;2015:146389. doi: 10.1155/2015/146389. Epub 2015 Feb 8.
9
Urine gamma-synuclein as a biomarker for the diagnosis of bladder cancer.尿γ-突触核蛋白作为膀胱癌诊断的生物标志物。
Oncotarget. 2016 Jul 12;7(28):43432-43441. doi: 10.18632/oncotarget.9468.
10
Vascular endothelial growth factor, carbonic anhydrase 9, and angiogenin as urinary biomarkers for bladder cancer detection.血管内皮生长因子、碳酸酐酶 9 和尿激肽原酶作为膀胱癌检测的尿生物标志物。
Urology. 2012 May;79(5):1185.e1-6. doi: 10.1016/j.urology.2012.01.016. Epub 2012 Mar 3.

引用本文的文献

1
Urinary mRNA-based biomarkers for non-muscle-invasive bladder cancer: a mini-review.基于尿液mRNA的非肌层浸润性膀胱癌生物标志物:一篇综述
Front Oncol. 2024 Aug 9;14:1441883. doi: 10.3389/fonc.2024.1441883. eCollection 2024.
2
Midkine (MDK) in Hepatocellular Carcinoma: More than a Biomarker.中胚层来源蛋白(MDK)在肝细胞癌中的作用:不止是一种生物标志物。
Cells. 2024 Jan 11;13(2):136. doi: 10.3390/cells13020136.
3
Diagnostic performance of Midkine ratios in fine-needle aspirates for evaluation of Cytologically indeterminate thyroid nodules.

本文引用的文献

1
Midkine is a serum and urinary biomarker for the detection and prognosis of non-small cell lung cancer.中期因子是一种用于非小细胞肺癌检测和预后评估的血清及尿液生物标志物。
Oncotarget. 2016 Dec 27;7(52):87462-87472. doi: 10.18632/oncotarget.13865.
2
Epidermal Growth Factor Receptor and Ki-67 as Predictive Biomarkers Identify Patients Who Will Be More Sensitive to Intravesical Instillations for the Prevention of Bladder Cancer Recurrence after Radical Nephroureterectomy.表皮生长因子受体和Ki-67作为预测性生物标志物可识别出对根治性肾输尿管切除术后预防膀胱癌复发的膀胱内灌注治疗更敏感的患者。
PLoS One. 2016 Nov 21;11(11):e0166884. doi: 10.1371/journal.pone.0166884. eCollection 2016.
3
细针抽吸物中中期因子比值对细胞学不确定甲状腺结节评估的诊断性能。
Diagn Pathol. 2021 Oct 25;16(1):92. doi: 10.1186/s13000-021-01150-y.
Clinicopathological and Prognostic Value of Ki-67 Expression in Bladder Cancer: A Systematic Review and Meta-Analysis.
Ki-67表达在膀胱癌中的临床病理及预后价值:一项系统评价与Meta分析
PLoS One. 2016 Jul 13;11(7):e0158891. doi: 10.1371/journal.pone.0158891. eCollection 2016.
4
Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline.非肌肉浸润性膀胱癌的诊断与治疗:AUA/SUO 指南。
J Urol. 2016 Oct;196(4):1021-9. doi: 10.1016/j.juro.2016.06.049. Epub 2016 Jun 16.
5
A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria who have a low probability of urothelial carcinoma.一种将尿液样本中的表型(临床特征)和基因型(基因表达)生物标志物相结合的分类指数,用于筛选出血尿患者中尿路上皮癌可能性较低的患者。
BMC Urol. 2015 Mar 27;15:23. doi: 10.1186/s12894-015-0018-5.
6
Serum levels for midkine, a heparin-binding growth factor, inversely correlate with angiotensin and endothelin receptor autoantibody titers in patients with macroangiopathy.在患有大血管病变的患者中,肝素结合生长因子中期因子的血清水平与血管紧张素和内皮素受体自身抗体滴度呈负相关。
Int Angiol. 2014 Aug;33(4):372-8.
7
Functional receptors and intracellular signal pathways of midkine (MK) and pleiotrophin (PTN).中期因子(MK)和多效生长因子(PTN)的功能性受体及细胞内信号通路
Biol Pharm Bull. 2014;37(4):511-20. doi: 10.1248/bpb.b13-00845.
8
Urine markers for detection and surveillance of bladder cancer.用于膀胱癌检测和监测的尿液标志物。
Urol Oncol. 2014 Apr;32(3):222-9. doi: 10.1016/j.urolonc.2013.06.001. Epub 2013 Sep 17.
9
Evaluation of midkine as a diagnostic serum biomarker in hepatocellular carcinoma.中期因子作为肝细胞癌诊断血清标志物的评估。
Clin Cancer Res. 2013 Jul 15;19(14):3944-54. doi: 10.1158/1078-0432.CCR-12-3363. Epub 2013 May 29.
10
Midkine mRNA level in peripheral blood mononuclear cells is a novel biomarker for primary non-small cell lung cancer: a prospective study.外周血单个核细胞中脑源神经营养因子 mRNA 水平是原发性非小细胞肺癌的一种新型生物标志物:一项前瞻性研究。
J Cancer Res Clin Oncol. 2013 Apr;139(4):557-62. doi: 10.1007/s00432-012-1357-1. Epub 2012 Dec 7.